A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

Sponsor
University of California and San Francisco

Protocol Number
UCSF 139511

To Learn More Call
201-510-0910

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Sponsor
Loxo Oncology

Protocol Number
Loxo Oncology LOXO-TRK-15002

To Learn More Call
201-510-0910

Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 years old

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00001894

To Learn More Call
201-510-0910

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC RV-CL-MCL-PI-003973

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Janssen

Protocol Number
PCI32765CAN3001-EXT

To Learn More Call
201-510-0910

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910

Older Breast Cancer Patients: Risk for Cognitive Decline

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown Cognition Study

To Learn More Call
201-510-0910